Why 10x Genomics, Inc.’s (TXG) Stock Is Down 5.54%
As of Friday, July 31, 10x Genomics, Inc.’s TXG share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Commentary & Analysis
Is 10x Genomics, Inc. (TXG) Overvalued?
We dive into why 10x Genomics, Inc. (TXG) could be considered overvalued on 2026-07-28, based on AAII’s Value Score and Grade.Tudor Pop
Why 10x Genomics, Inc.’s (TXG) Stock Is Up 6.34%
As of Tuesday, July 21, 10x Genomics, Inc.’s TXG share price has surged by 6.34%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why 10x Genomics, Inc.’s (TXG) Stock Is Down 6.08%
As of Thursday, July 16, 10x Genomics, Inc.’s TXG share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why 10x Genomics, Inc.’s (TXG) Stock Is Up 5.87%
As of Tuesday, July 14, 10x Genomics, Inc.’s TXG share price has surged by 5.87%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | TXG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,275.4 | $1,774.7 | 71% |
|
| Shares Out (Mil) | 128.3 | 94.8 | 68% |
|
| Institutional Ownership | 92.3% | 90.1% | 61% |
|
| Float (Mil) | 114.8 | 69.9 | 64% |
|
| Beta | 2.04 | 1.20 | 93% |
|
| Avg Daily Volume (000s) | 2,523 | 838 | 86% |
|
| Price Change (52-week) |
253.1% | 81.0% | 98% |
|
| Growth | TXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.6% | 7.8% | 76% |
|
| Net Income (5yr) | 39.6% | (13.7%) | 90% |
|
| EPS (5yr) | 42.1% | 0.7% | 89 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (13.1%) | (15.0%) | 56% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 3 | |
| Current EPS | ($0.017) | $0.000 | $0.207 | |
| Month Ago EPS | ($0.017) | $0.000 | $0.200 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.043) | ($0.107) | $0.200 | |
| Year/Year Chg | (83.8%) | (100.0%) | (191.7%) | |
| Financials | TXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $639 | $763 | 44% |
|
| Net Income (TTM) (Mil) | ($23) | ($14) | 23% |
|
| EPS (TTM) | ($0.180) | ($0.200) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | $128 | $53 | 55% |
|
| Net Cash Flow (TTM) (Mil) | $113 | ($5) | 79% |
|
| Long-Term Debt (Q1) (Mil) | $70 | $270 | 42% |
|
| Enterprise Value (Q1) (Mil) | $5,643 | $2,430 | 65% |
|
| Valuation | TXG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.83 | 3.00 | 87% |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | TXG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.7% | 47.6% | 81% |
|
| Net Margin | (3.5%) | (2.9%) | 27% |
|
| ROA | (2.4%) | (3.2%) | 34% |
|
| ROE | (3.0%) | (4.5%) | 33% |
|
| Liabilities to Assets | 19.8% | 43.0% | 12% |
|
| F-Score | 5 | 5 | 51% |
|
10x Genomics, Inc. did not pass any screens on 7/30/2026.
